Replies to post #238305 on Biotech Values

[DewDiligence]

FOLD spins off gene-therapy subsidiary, Caritas Therapeutics, which will go public via a reverse-merger with ARYD SPAC:

https://www.globenewswire.com/news-release/2021/09/29/2305173/15991/en/Amicus-Therapeutics-and-ARYA-Sciences-Acquisition-Corp-IV-Announce-Formation-of-a-Next-Generation-Genetic-Medicine-Company-Caritas-Therapeutics.html

Following the reverse-merger, FOLD will retain a 36% equity stake in Caritas.